Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:593-599
doi: 10.1161/CIRCULATIONAHA.106.650747
CLINICAL PERSPECTIVE
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erdogan, D.
Right arrow Articles by Muderrisoglu, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erdogan, D.
Right arrow Articles by Muderrisoglu, H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Clinical Studies
Right arrow Echocardiography
Right arrow Risk Factors

(Circulation. 2007;115:593-599.)
© 2007 American Heart Association, Inc.


Hypertension

Effects of Normal Blood Pressure, Prehypertension, and Hypertension on Coronary Microvascular Function

Dogan Erdogan, MD; Ibrahim Yildirim, MD; Ozgur Ciftci, MD; Ismail Ozer, MD; Mustafa Caliskan, MD; Hakan Gullu, MD; Haldun Muderrisoglu, MD, FESC

From Baskent University, Konya Teaching and Medical Research Center, Cardiology Department (D.E., O.C., M.C., H.G., H.M.) and Internal Medicine Department, Nephrology Division (I.Y., I.O.), Konya, Turkey.

Correspondence to Dogan Erdogan, MD, Baskent University, Konya Teaching and Medical Research Center, Cardiology Department, Hoca Cihan Mah, Saray Cad, No. 1, Selcuklu, Konya, Turkey. E-mail aydoganer{at}yahoo.com or aydoganer@hotmail.com

Received July 10, 2006; accepted November 27, 2006.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background— The assessment of coronary flow reserve (CFR) by transthoracic Doppler echocardiography has recently been introduced into clinical practice, and reduced CFR has been suggested to be a sensitive indicator of hypertensive end-organ damage; however, to date, this methodology has not been used to evaluate CFR in subjects with prehypertension. Accordingly, the present study was designed to evaluate CFR in subjects with prehypertension.

Methods and Results— We measured CFR of 40 subjects with prehypertension, 60 patients with hypertension, and 50 normotensive healthy volunteers using transthoracic Doppler echocardiography. None of the subjects had any systemic disease. Age, gender, body mass index, heart rate, lipid profiles, fasting glucose levels, and hemoglobin were similar among the 3 groups. CFR was significantly lower in the hypertension group than in the prehypertension and control groups; in addition, it was significantly lower in subjects with prehypertension than in control subjects (2.23±0.47, 2.54±0.48, and 2.91±0.53, respectively). Furthermore, we found that prehypertension (ß=–0.31, P<0.01) and hypertension (ß=–0.57, P<0.01) were significant predictors of lower CFR in a multivariable model that adjusted for other variables. CFR was significantly and inversely correlated with age (r=–0.20, P=0.01), systolic blood pressure (r=–0.51, P<0.01), diastolic blood pressure (r=–0.47, P<0.01), high-sensitivity C-reactive protein levels (r=–0.21, P=0.01), left atrium diameter (r=–0.22, P<0.01), mitral E deceleration time (r=–0.19, P=0.02), and mitral A velocity (r=–0.27, P<0.01), whereas mitral E/A ratio was significantly and positively correlated with CFR (r=0.26, P<0.01).

Conclusions— CFR is impaired in subjects with prehypertension, but this impairment is not as severe as that in hypertension.


Key Words: blood pressure • echocardiography • blood flow • hypertension


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Prehypertension, formerly defined as high-normal and above-optimal blood pressure (BP),1 is defined in a normotensive person as systolic BP 120 to 139 mm Hg and/or diastolic BP 80 to 89 mm Hg based on ≥2 properly measured, seated BP readings on each of 2 or more office visits.2 Compared with normal BP, prehypertension is associated with an increase in cardiovascular morbidity and mortality.3,4 The mechanism of excess risk from prehypertension is presumed to be the same as that from hypertension. It has also been shown that prehypertension is associated with subclinical atherosclerosis, including increased coronary atherosclerosis, and target-organ damage.5–7

Clinical Perspective p 599

The mechanism involved in microvascular dysfunction leading to myocardial ischemia and angina in patients with hypertension without coronary artery disease is not yet clear. Left ventricular hypertrophy in subjects with elevated BP is a well-known factor responsible for impairment of coronary vasodilator capacity8,9; however, angina and impairment of coronary vasodilating capacity may occur in some hypertensive individuals in the absence of left ventricular hypertrophy.10,11 Abnormalities in coronary reactivity may also exist in asymptomatic hypertensive individuals.12 To date, the mechanisms that may be involved in the alteration of coronary flow reserve (CFR) in hypertension have not been studied extensively in humans because of the complex and invasive techniques used to evaluate CFR. Pharmacological stress transthoracic Doppler echocardiography (TTDE) is a relatively recent, useful, and highly reproducible tool to evaluate CFR, and its feasibility has been validated in several studies.13 Furthermore, it has recently been shown that CFR measured by TTDE has an excellent correlation with CFR measured by positron emission tomography, which has been validated as the "gold standard" for CFR measurement.14

Although substantial evidence supports the contention that prehypertension is associated with atherosclerosis and target-organ damage, to date there has been no study that investigated CFR in these patients with TTDE. In the present study, we measured CFR in normotensive subjects, in subjects with prehypertension, and in newly diagnosed and never-treated patients with established hypertension without excessive left ventricular hypertrophy using TTDE.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Study Population
The overall study population consisted of 150 subjects: 40 subjects with prehypertension (group I), 60 patients with hypertension (group II), and 50 healthy volunteers with normal BP (group III). Their demographic and clinical data are shown in Table 1. The inclusion criterion was age 18 to 55 years. All subjects, including those with prehypertension and hypertension, were asymptomatic and free of coronary artery disease. Exclusion criteria were presence of any systemic disease, such as hemolytic, hepatic, and renal diseases, or any disease that could cause CFR impairment (eg, diabetes mellitus: fasting plasma glucose level measured on 3 separate days in 1 week >126 mg/dL [7.0 mmol/L] or impaired oral glucose tolerance test; or fasting plasma glucose <126 mg/dL [7.0 mmol/L] but 2-hour plasma glucose after a 75-g oral glucose challenge >140 mg/dL [7.8 mmol/L], and excessive alcohol consumption [>120 g/d]). Normotensive healthy control subjects had no history of treatment with antihypertensive drugs. Subjects with prehypertension and patients with established hypertension had not previously taken any antihypertensive therapy. Subjects using any vasoactive drug and those who had ST-segment or T-wave changes specific for myocardial ischemia, Q waves, and incidental left bundle-branch block on ECG were excluded from the study. In addition, patients with a left ventricular mass index >126 g/m in men and >99 g/m in women15 were excluded from the study to avoid the confounding effects of left ventricular hypertrophy on CFR. Written informed consent was obtained from each subject, and the institutional ethics committee approved the study protocol.


View this table:
[in this window]
[in a new window]

 
TABLE 1. Demographic and Biochemical Characteristics of Each Study Group

Blood Pressure Measurement
In accordance with American Heart Association guidelines, BP was measured with a mercury sphygmomanometer in an office setting; the first and fifth phases of Korotkoff sounds were used for systolic and diastolic BP. Appropriate cuff sizes were chosen for each subject’s arm circumference. BP was measured 3 times by skilled, trained physicians after subjects had rested for 15 minutes in the sitting position, and the average of the measurements was recorded. Physical examination included measurement of height (centimeters) and weight (kilograms), and a resting 12-lead ECG was recorded.

Diagnosis of Prehypertension, Hypertension, and Normotension
In each subject, BP was measured on at least 3 separate days after a 15-minute period of comfortable, seated rest, and these measurements were averaged. On the basis of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,2 prehypertension was defined as systolic BP between 120 and 139 mm Hg and/or diastolic BP between 80 and 89 mm Hg. Individuals who had systolic BP ≥140 mm Hg and/or a diastolic BP ≥90 mm Hg were diagnosed as hypertensive. Control subjects who had systolic BP <120 mm Hg and diastolic BP <80 mm Hg were diagnosed as normotensive controls.

Echocardiographic Examination
Each subject was examined with an Acuson Sequoia C256 echocardiography system equipped with 3V2c and 5V2c broadband transducers with second harmonic capability (Acuson Corp, Mountain View, Calif). Two-dimensional, M-mode, and subsequent transthoracic Doppler harmonic echocardiography examinations were performed on each subject.

Left Ventricular Mass Determination
Left ventricular mass was calculated from M-mode records taken on parasternal long-axis images according to the formula below (corrected American Society of Echocardiography cube method)15,16:

LVM=0.8x(1.04[(IVSd+PWd+LVDD)3–(LVDD)3])+0.6 g

where LVM is left ventricular mass, IVSd is interventricular septum thickness at diastole, PWd is posterior wall thickness at diastole, and LVDD is left ventricular diastolic diameter. To take into account differences in body size that might influence heart size, left ventricular mass was divided by height to create a left ventricular mass index.

CFR Measurement
Visualization of the distal left anterior descending coronary artery (LAD) was performed with a modified, foreshortened, 2-chamber view obtained by sliding the transducer on the upper part and medially from an apical 2-chamber view. Coronary flow in the distal LAD was examined by color Doppler flow mapping over the epicardial part of the anterior wall, with the color Doppler velocity range set in the range of 8.9 to 24.0 cm/s.17 The left ventricle was imaged on the long-axis cross section, and the ultrasound beam was then inclined laterally. Next, coronary blood flow in the LAD (middle to distal) was searched by color Doppler flow mapping (Figure 1). All subjects had Doppler recordings of the LAD with a dipyridamole infusion at a rate of 0.56 mg/kg over 4 minutes. By placing the sample volume on the color signal, spectral Doppler of the LAD showed the characteristic biphasic flow pattern, with larger diastolic and smaller systolic components (Figure 1). Coronary diastolic peak velocities were measured at baseline and after dipyridamole by averaging the highest 3 Doppler signals for each measurement. CFR was defined as the ratio of hyperemic to baseline diastolic peak velocities.17 CFR ≥2.0 was considered normal.8,9,13,17 CFR measurement was achieved in 150 (98.6%) of the 152 subjects. To test the reproducibility of CFR measurement, in 20 subjects assigned randomly, the measurement was repeated 2 days later. Intraobserver intraclass correlation coefficients for coronary flow measurements were 0.862 and 0.822 (baseline and hyperemic diastolic peak velocities, respectively), and for CFR value, the coefficient was 0.878.


Figure 1181032
View larger version (127K):
[in this window]
[in a new window]

 
Figure 1. Mid to distal segment of LAD in color-coded TTDE; spectral Doppler coronary blood flow by sampling in mid to distal segment of LAD. S indicates systole; D, diastole.

Statistical Analyses
The analyses were performed with SPSS 9.0 (SPSS for Windows 9.0, Chicago, Ill). Data are expressed as mean±SD. Groups were compared with {chi}2 test with regard to categorical variables. One-way ANOVA followed by Tukey’s test or Kruskal-Wallis test (comparison of a characteristic across the 3 study groups if that characteristic did not have a normal distribution, such as high-sensitivity C-reactive protein and triglycerides) was used to compare continuous variables. Pearson’s correlation test was used to test the associations between coronary flow measurements and the study variables. Multivariable analysis was used to assess associations of CFR with potential confounders via a multivariate linear regression model. A probability value <0.05 was considered significant.

The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Clinical Characteristics of the Study Population
The general characteristics and risk factors for coronary artery disease of the study population are presented in Table 1. Age, gender, heart rate, lipid profiles, fasting glucose levels, and hemoglobin were similar among the 3 groups. Although the mean value of body mass index was similar within the groups, the percentage of obesity (body mass index ≥30 kg/m2) was significantly higher in the prehypertension group than in the other 2 study groups. The frequency of metabolic syndrome was significantly lower in the control group than in the other 2 groups. The serum high-sensitivity C-reactive protein level did not differ significantly between the prehypertension and control groups or between the prehypertension and hypertension groups; however, it was significantly higher in the hypertension group than in the control group. Systolic and diastolic BP were significantly higher in the hypertension group than in either the prehypertension or control groups; in addition, BP measurements were significantly higher in subjects with prehypertension than in control subjects.

Analyses of Echocardiographic Measurements
Interventricular septum thickness and left atrial diameter were significantly greater in the hypertension group than in the control group, although they did not differ significantly between the prehypertension and control groups or between the prehypertension and hypertension groups. Left ventricular posterior wall thickness, end-diastolic diameter, systolic diameter, and ejection fraction were similar among the 3 groups. Left ventricular mass index was significantly higher in the hypertension group than in the other 2 groups. Mitral E deceleration time was significantly higher in the hypertension group than in the control group. Other left ventricular diastolic parameters were slightly different between the hypertension and control groups, but these differences did not reach statistical significance (Table 2).


View this table:
[in this window]
[in a new window]

 
TABLE 2. Data From Echocardiographic Examinations of the Study Groups

Analysis of CFR Measurements
Baseline and peak heart rates were similar among the 3 groups. Peak systolic and diastolic BP were significantly higher in patients with hypertension than in those with prehypertension or control subjects. In addition, peak systolic and diastolic BP were significantly higher in the prehypertension group than in the control group (Table 2). Baseline diastolic peak flow velocity of the LAD was similar between the prehypertension and control groups and between the prehypertension and hypertension groups; however, it was slightly higher in the hypertension group than in the control group (P=0.06). Compared with the control group, hyperemic diastolic peak flow velocity was significantly lower in the hypertension group and slightly lower in the prehypertension group (Table 2). Accordingly, CFR was significantly lower in the hypertension and prehypertension groups than in the control group. In addition, hyperemic diastolic peak flow velocity was slightly different and CFR was significantly different between the prehypertension and hypertension groups (CFR: 2.23±0.47, 2.54±0.48, and 2.91±0.53 in the hypertension, prehypertension, and control groups, respectively; Figure 2). None of the control subjects had abnormal CFR (<2); however, 7 subjects with prehypertension (18%) and 21 patients with hypertension (35%) had abnormal CFR (Table 2). Furthermore, in multivariable analysis in which CFR was taken as a dependent variable and the classification status of the subjects (prehypertension, hypertension, or control), age, body mass index, lipids, and other confounders, including left ventricular mass index, diastolic function parameters, and high-sensitivity C-reactive protein, were taken as independent variables, we found that the presence of prehypertension (ß=–0.31, P<0.01) and hypertension (ß=–0.57, P<0.01) were significant predictors of lower CFR.


Figure 2181032
View larger version (24K):
[in this window]
[in a new window]

 
Figure 2. CFR measurements were significantly different among the 3 groups. PHT indicates prehypertension.

Correlation Analyses
CFR was significantly and inversely correlated with age (r=–0.197, P=0.01), systolic BP (r=–0.507, P<0.0001), diastolic BP (r=–0.472, P<0.0001), high-sensitivity C-reactive protein levels (r=–0.205, P=0.01), left atrium diameter (r=–0.223, P=0.006), mitral E deceleration time (r=–0.185, P=0.02), and mitral A velocity (r=–0.273, P=0.001), whereas the mitral E/A ratio was significantly and positively correlated with CFR (r=0.263, P=0.001). In addition, total cholesterol and low-density lipoprotein cholesterol trended toward a negative correlation and HDL cholesterol toward a positive correlation with CFR.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Coronary artery disease and stroke are the most common forms of target-organ damage and the most common causes of mortality associated with hypertension. Although substantial evidence supports the premise that hypertension impairs CFR, no prior data exist regarding the impact of hypertension, prehypertension, and normal BP on CFR in subjects without any clinical evidence of coronary artery disease. In the present study, we aimed to evaluate CFR and thus coronary microvascular function in subjects with prehypertension, in patients with established hypertension, and in normotensive healthy controls using TTDE. We found that CFR was significantly impaired in patients with prehypertension compared with normotensive subjects; however, in subjects with prehypertension, impairment of CFR was not as severe as in those with hypertension.

It has been suggested that impairment of CFR may occur very early in hypertension, before hypertrophy is apparent, and thus may cause subsequent ischemia and fibrosis.18 Reduced CFR is largely the result of changes in minimal coronary resistance that are independent of vascular tone.12,18–20 Therefore, structural changes in the coronary vasculature are most likely to be the major contributors to impaired CFR. These structural changes may be qualitatively similar to the well-described effects of hypertension on the peripheral circulation.21 Furthermore, quantitative histological studies performed on septal biopsy tissue showed that reduced coronary dilatory capacity was associated with increased arteriolar media area and perivascular and interstitial fibrosis in patients with arterial hypertension and angina pectoris in the absence of relevant coronary artery stenosis.12 These conditions are sensitive indicators of hypertensive target-organ damage.12,19 The presence of subclinical hypertensive target-organ damage signals a condition of increased risk for cardiovascular and renal morbidity and mortality.22 Therefore, the search for impaired CFR may add valuable information to the cardiovascular risk assessment of hypertensive patients.

Recently, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure2 provided guidelines for the new category of BP levels between normal BP (systolic BP <120 mm Hg and diastolic BP <80 mm Hg) and established hypertension (systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg). This new category between normal BP and established hypertension, prehypertension, includes a population at high risk for developing hypertension and in whom lifestyle modifications are recommended.2 However, the absolute reduction in the incidence of new-onset hypertension with the most successful lifestyle modification was only 8% in the Trials of Hypertension Prevention.23 The most important epidemiological data on high-normal and above-normal BP (ie, prehypertension) come from 2 analyses of the Framingham Heart Study data. The first one included 9745 subjects.24 Compared with the optimal BP group (<120/80 mm Hg), the subjects with above-normal BP (systolic BP between 120 and 129 mm Hg or diastolic BP between 80 and 84 mm Hg) or high-normal BP (systolic BP between 130 and 139 mm Hg or diastolic BP between 85 and 89 mm Hg), who were combined into the prehypertension category under the guidelines of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, had a markedly increased risk of developing hypertension within 4 years (relative risk 11.6 for subjects 35 to 64 years of age and 5.5 for subjects ≥65 years of age). The second analysis from the Framingham Heart Study population included 6859 subjects followed up for 10 years, and this analysis showed that compared with optimal BP, high-normal BP was associated with a risk factor–adjusted hazard ratio for cardiovascular disease of 2.5 (95% confidence interval [CI] 1.6 to 4.1) in women and 1.6 (95% CI 1.1 to 2.2) in men.25

Although prehypertension (formerly high-normal and above-optimal BP) has been widely studied in the past, it remains a matter of controversy, especially with regard to its treatment. Its prognostic importance and risk profile for target-organ damage have not yet been clearly established, and the term "prehypertension" has yet to be widely adopted. Several previous studies have demonstrated that subjects with prehypertension are at increased cardiovascular risk and may already have evidence of target-organ damage, such as impairment of ventricular relaxation or microalbuminuria.25,26 In line with the suggestions mentioned above, we found that, compared with normotensive control subjects, patients with prehypertension had impaired CFR, which is a surrogate marker of hypertensive target-organ damage. Several possible mechanisms could explain the reduction in CFR in hypertensive patients. First, baseline coronary flow may be increased because of increments in the tone of coronary resistance vessels that result from higher BP and extravascular compression in the presence of left ventricular hypertrophy caused by greater left ventricular wall stress.11,27 Second, the maximal coronary flow response to physiological or pharmacological stimuli may be limited by a reduction in the overall maximal cross-sectional area of the microcirculatory bed, which is induced by vascular changes in the intramyocardial coronary arteries.28,29 However, because coronary blood flow predominantly occurs during diastole, an impairment in left ventricular diastolic function may also play an important role in CFR impairment in hypertension.30 In line with these suggestions, we found that there was an association between left ventricular diastolic function parameters and CFR.

In conclusion, these data provide evidence of impaired CFR, or impaired coronary microvascular function, in subjects with prehypertension. Our results are consistent with the idea that the presence of mildly elevated BP is associated with an abnormal coronary flow response.


*    Acknowledgments
 
Disclosures

None.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157: 2413–2446.[Abstract]
  2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–1252.[Abstract/Free Full Text]
  3. Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? Stroke. 2005; 36: 1859–1863.[Abstract/Free Full Text]
  4. Mainous AG III, Everett CJ, Liszka H, King DE, Egan BM. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol. 2004; 94: 1496–1500.[CrossRef][Medline] [Order article via Infotrieve]
  5. Nesbitt SD, Julius S, Leonard D, Egan BM, Grozinski M. Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY study. Am J Hypertens. 2005; 18: 980–985.[CrossRef][Medline] [Order article via Infotrieve]
  6. Cordero A, Laclaustra M, Leon M, Grima A, Casasnovas JA, Luengo E, del Rio A, Ferreira I, Alegria E. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment: a Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy. Am J Hypertens. 2006; 19: 189–196.[CrossRef][Medline] [Order article via Infotrieve]
  7. Lee JE, Kim YG, Choi YH, Huh W, Kim DJ, Oh HY. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006; 47: 962–967.[Abstract/Free Full Text]
  8. Antony I, Nitenberg A, Foult JM, Aptecar E. Coronary vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy. J Am Coll Cardiol. 1993; 22: 514–520.[Abstract]
  9. Galderisi M, de Simone G, Cicala S, De Simone L, D’Errico A, Caso P, de Divitiis O. Coronary flow reserve in hypertensive patients with appropriate or inappropriate left ventricular mass. J Hypertens. 2003; 21: 2183–2188.[CrossRef][Medline] [Order article via Infotrieve]
  10. Brush JE, Cannon RO III, Schenke WH, Bonow RO, Leon MB, Maron BJ, Ebstein SE. Angina due to microvascular disease in hypertensive patients without left ventricular hypertrophy. N Eng J Med. 1988; 319: 1302–1307.[Abstract]
  11. Kozakova M, Palombo C, Pratali L, Pittella G, Galetta F, L’Abbate A. Mechanisms of coronary flow reserve impairment in human hypertension: an integrated approach by transthoracic and transesophageal echocardiography. Hypertension. 1997; 29: 551–559.[Abstract/Free Full Text]
  12. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation. 1993; 88: 993–1003.[Abstract/Free Full Text]
  13. Caiati C, Zedda N, Montaldo C, Montischi R, Iliceto S. Contrast-enhanced transthoracic second harmonic echo Doppler with adenosine: a noninvasive, rapid and effective method for coronary flow reserve assessment. J Am Coll Cardiol. 1999; 34: 122–130.[Medline] [Order article via Infotrieve]
  14. Saraste M, Koskenvuo J, Knuuti J, Toikka J, Laine H, Niemi P, Sakuma H, Hartiala J. Coronary flow reserve: measurement with transthoracic Doppler echocardiography is reproducible and comparable with positron emission tomography. Clin Physiol. 2001; 21: 114–122.[CrossRef][Medline] [Order article via Infotrieve]
  15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W; American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7: 79–108.[Abstract/Free Full Text]
  16. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450–458.[CrossRef][Medline] [Order article via Infotrieve]
  17. Erdogan D, Gullu H, Caliskan M, Yildirim I, Tok D, Muderrisoglu H. Coronary flow reserve is preserved in white-coat hypertension. Heart. 2006; 92: 1109–1112.[Abstract/Free Full Text]
  18. Laine H, Raitakari OT, Niinikoski H, Pitkanen OP, Iida H, Viikari J, Nuutila P, Knuuti J. Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol. 1998; 32: 147–153.[Abstract/Free Full Text]
  19. Frohlich ED. Fibrosis and ischemia: the real risks in hypertensive heart disease. Am J Hypertens. 2001; 14: 194S–199S.[CrossRef][Medline] [Order article via Infotrieve]
  20. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res. 1991; 69: 107–115.[Abstract/Free Full Text]
  21. Jennings GL, Dilley RJ. Left ventricular remodelling impacts on coronary flow reserve in hypertensive patients: is there a vascular mechanism? J Hypertens. 2002; 20: 1291–1293.[CrossRef][Medline] [Order article via Infotrieve]
  22. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E, Vettoretti S, Bezante GP, Del Sette M, Deferrari G, Pontremoli R. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005; 45: 991–996.[Abstract/Free Full Text]
  23. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, phase II. Arch Intern Med. 1997; 157: 657–667.[Abstract]
  24. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001; 358: 1682–1686.[CrossRef][Medline] [Order article via Infotrieve]
  25. Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001; 345: 1291–1297.[Abstract/Free Full Text]
  26. Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis. 2003; 41: 588–595.[CrossRef][Medline] [Order article via Infotrieve]
  27. Polese A, De Cesare N, Montorsi P, Fabbiocchi F, Guazzi M, Loaldi A, Guazzi MD. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation. 1991; 83: 845–853.[Abstract/Free Full Text]
  28. Brush JE Jr, Cannon RO III, Schenke WH, Bonow RO, Leon MB, Maron BJ, Epstein SE. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med. 1988; 319: 1302–1307.[Abstract]
  29. Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, Ganz P, Alexander RW. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation. 1993; 87: 86–93.[Abstract/Free Full Text]
  30. Galderisi M, Cicala S, Caso P, De Simone L, D’Errico A, Petrocelli A, de Divitiis O. Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am J Cardiol. 2002; 90: 860–864.[CrossRef][Medline] [Order article via Infotrieve]

 

CLINICAL PERSPECTIVE

Substantial evidence suggests that hypertension impairs coronary flow reserve (CFR), which suggests that coronary microvascular function and impairment of the CFR may occur very early in hypertension, before hypertrophy is apparent. Structural changes in the coronary vasculature are most likely to be the major contributors to impaired CFR. Therefore, evaluation of CFR may add valuable information to the cardiovascular risk assessment of hypertensive patients. Pharmacological stress transthoracic Doppler echocardiography is a useful and highly reproducible tool for evaluation of CFR, and it has been shown that CFR measured by transthoracic Doppler echocardiography has an excellent correlation with CFR measured by positron emission tomography, which has been validated as a "gold standard" for CFR measurement. Growing evidence shows that prehypertension (systolic blood pressure 120 to 139 mm Hg and/or diastolic blood pressure 80 to 89 mm Hg) is associated with target-organ damage, and prehypertensive subjects are at high risk for developing hypertension. The present study, by assessing CFR in prehypertensive, hypertensive, and normotensive individuals, provides novel information on the potential impact of prehypertension on target-organ damage.




This article has been cited by other articles:


Home page
Eur J EchocardiogrHome page
P. Meimoun and C. Tribouilloy
Non-invasive assessment of coronary flow and coronary flow reserve by transthoracic Doppler echocardiography: a magic tool for the real world
Eur J Echocardiogr, July 1, 2008; 9(4): 449 - 457.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. Williams
The year in hypertension.
J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1803 - 1817.
[Full Text] [PDF]


Home page
HypertensionHome page
L. Wang, T. Y. Wong, A. R. Sharrett, R. Klein, A. R. Folsom, and M. Jerosch-Herold
Relationship Between Retinal Arteriolar Narrowing and Myocardial Perfusion: Multi-Ethnic Study of Atherosclerosis
Hypertension, January 1, 2008; 51(1): 119 - 126.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erdogan, D.
Right arrow Articles by Muderrisoglu, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erdogan, D.
Right arrow Articles by Muderrisoglu, H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Clinical Studies
Right arrow Echocardiography
Right arrow Risk Factors